Disarm debuts with $30M series A

Disarm Therapeutics Inc. (Cambridge, Mass.) closed a $30 million series A round led by existing investor Atlas Venture. New investors Lightstone Ventures and AbbVie Ventures also participated.

Disarm is developing small molecule inhibitors of sterile alpha and TIR motif containing 1 (SARM1) to prevent axonal degeneration in a range of neurological disorders including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma and peripheral neuropathies. ...